SCHEMBL7097753

SCHEMBL7097753

OBc1ccc(Cl)cc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 4/20 0.38
▸ PPARA Q07869 4/20 0.38
▸ KMT2A Q03164 1/20 0.36
▸ HSD17B10 Q99714 3/20 0.34
▸ TSHR P16473 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ KMO O15229 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ HPGD P15428 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ ALOX15 P16050 1/20 0.32
▸ ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21791937 0.84 ALDH1A1 (0.36) PPARGPPARAKMT2AHSD17B10TSHR
SCHEMBL27678216 0.77 CYP3A4 (0.41) HSD17B10TSHRALDH1A1CYP3A4TDP1
SCHEMBL21737149 0.77 CCR2 (0.34) PPARGPPARAKMT2ATSHRALDH1A1
SCHEMBL14261346 0.76 TSHR (0.48) KMT2AHSD17B10TSHRALDH1A1CYP3A4
SCHEMBL13107429 0.76 CES2 (0.43) KMT2AALDH1A1TDP1ALOX12
SCHEMBL14140533 0.73 NFE2L2 (0.36) KMT2AHSD17B10ALDH1A1CYP3A4TDP1
SCHEMBL17366292 0.73 MAP2K2 (0.33) —
SCHEMBL530450 0.72 — —
SCHEMBL29443091 0.72 — —
SCHEMBL13300191 0.71 TSHR (0.48) KMT2AHSD17B10TSHRALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230134932-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-04 — — US disclosed
US-20230134932-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-04 — — US disclosed
US-11239426-B2 Electroactive compounds LG CHEM, LTD. 2022-02-01 — — US disclosed
WO-2021238587-A1 MICROMOLECULAR OXATHIAZINE DERIVATIVE AND USE THEREOF 四川大学华西医院 2021-12-02 — — WO disclosed
WO-2018097937-A1 ELECTROACTIVE COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2018-05-31 — — WO disclosed
CN-102428064-A Novel pesticide SYNGENTA LTD 2012-04-25 — — CN disclosed
CN-1972695-A Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmethanones ANACOR PHARMACEUTICALS INC (US) 2007-05-30 — — CN disclosed
EP-1339725-A2 DNA METHYL TRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2003-09-03 — — EP disclosed
WO-2002044184-A2 DNA METHYL TRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2002-06-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230134932-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 PPARG 4693/4885PPARA 4678/4885KMT2A 1931/4885
US-11239426-B2 Electroactive compounds KCNN2, HCN2, KCNN3 PPARG 1259/4885PPARA 1817/4885KMT2A 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback